Molecular Diagnostics News and Research

RSS

UK’s first Centre for Phage Research highlights Actiphage in the KTN UK Phage Innovation Showcase

Tuberculosis is caused by a bacterium that has evolved to evade the body’s immune system; now, its natural enemy, a phage, is being used to detect the infection at an early stage.

18 May 2023

New process for automated and highly accurate reporting of NGS-based clonality testing

A new research paper was published in Oncotarget's Volume 14 on May 12, 2023, entitled, "Development and implementation of an automated and highly accurate reporting process for NGS-based clonality testing."

16 May 2023

Overcoming challenges in Point of Care diagnostics in veterinary medicine

In this interview, we speak to Dr. Naomi Urbina, senior scientist at Fortis, about recent developments in Point of Care diagnostics in veterinary medicine, and about how Nanocomposix services can help overcome potential challenges in the field.

From nanoComposix 24 Apr 2023

How can Europe tackle its unfinished tuberculosis business?

A recent Eurosurveillance journal editorial discussed the progress in the EU/EEA, between 2018 and 2021, towards achieving the 2030 targets for TB elimination.

27 Mar 2023

Point-of-care test identifies patients who may benefit from hypnosis interventions for pain treatment

Hypnosis is an effective treatment for pain for many individuals but determining which patients will benefit most can be challenging. Hypnotizability testing requires special training and in-person evaluation rarely available in the clinical setting.

15 Mar 2023

Women-focused diagnostics start-up wins INTEGRA Biosciences’ EVOLVE pipettes

Nanopath has been chosen as the first winner of the recently launched INTEGRA supports start-ups competition.

From INTEGRA Biosciences 15 Mar 2023

Ultrafast PCR technology shortens the test time by 10-fold

PCR technology is a molecular diagnostics technology that detects target nucleic acids by amplifying the DNA amount. It has brought marked progress in the life sciences field since its development in 1984.

3 Mar 2023

BioEcho receives patent for its EchoLUTION™ technology in the U.S. and Japan

BioEcho announces the grant of two patents for the innovative EchoLUTION™ technology transforming established nucleic acid extraction procedures.

From BioEcho Life Sciences GmbH 17 Feb 2023

"AutoPLP" technique enables rapid, accurate detection of mutating bacteria and viruses

As we now know from our experience with the COVID-19 pandemic, the microbes responsible for some infections can rapidly mutate into variants that evade detection and treatment.

15 Feb 2023

Integrated NGS system can deliver accurate, genomics-based diagnoses to accelerate treatment for myeloid neoplasms

Identifying recurrent genetic alterations in myeloid neoplasms has improved diagnosis and expanded targeted treatments available to patients. However, treatment initiation can be delayed by the variable and lengthy turnaround times involved in testing for these alterations.

7 Feb 2023

A slight increase in Mpox cases across the globe, along with an increase in deaths

The WHO discusses genomic sequencing of the Mpox virus, in addition to providing public and clinical health links between HIV and Mpox.

24 Jan 2023

UK set to boost genomics expertise through a landmark partnership with Thailand

UK patients will benefit from a new partnership with Thailand to share expertise of genome sequencing, collaborate in research, education and training opportunities, knowledge exchange and genomics data handling.

20 Jan 2023

New type of CRISPR gene scissors discovered

Like humans, bacteria and archaea can be attacked by viruses. These microorganisms have developed their own immune defense strategies against their pathogens.

4 Jan 2023

Using 3D patient tumor avatars to guide cancer treatment decisions

At any time, most cancer patients are receiving a treatment that does not significantly benefit them while enduring bodily and financial toxicity.

20 Dec 2022

Assessing clinical adoption of 2017 guidelines for interpretation and reporting of sequence variants in cancer

The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, has published a report that was designed to assess clinical adoption, identify classification inconsistencies, and evaluate implementation barriers for the 2017 report, "Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.

15 Dec 2022

Whole-genome sequencing reveals five new subgroups of chronic lymphocytic leukemia

A collaborative study led by the University of Oxford as part of the UK's 100,000 Genomes Project, published in Nature Genetics today, has defined five new subgroups of the most common type of blood cancer, chronic lymphocytic leukemia (CLL) and associated these with clinical outcomes.

16 Nov 2022

Protein levels in lung tumors may predict prognosis, improve treatment and diagnostics

Lung cancer is the leading cause of cancer deaths globally and a top cause of cancer deaths in the Military Health System.

15 Nov 2022

Serbia’s high-throughput genetic sequencing implementation | BGI Perspectives

On the occasion of the 17th International Conference of Genomics (ICG-17) jointly organized by BGI Genomics in Riga, Dr. Ivana Morić, a research professor from the Institute of Molecular Genetic and Genetic Engineering (IMGGE) at the University of Belgrade shared first-hand insights about the implementation of high-throughput sequencing in Serbia and its exciting future.

From BGI Genomics 14 Nov 2022

Handheld diagnostic all-in-one lab kit could increase the speed and volume of disease testing

Using swarms of pinhead-sized magnets inside a handheld, all-in-one lab kit, UCLA researchers have developed a technology that could significantly increase the speed and volume of disease testing, while reducing the costs and usage of scarce supplies.

11 Nov 2022

Llusern debuts Lodestar UTI molecular diagnostic platform at Medica 2022

UK diagnostics manufacturer, Llusern Scientific, will preview its Lodestar DX molecular platform at Medica 2022 in Dusseldorf (14-17 November).

From Llusern Scientific Ltd. 7 Nov 2022